Christelle Soudy

Christelle Soudy

Auto-generated profile, based on publicly available information

Christelle Soudy

The Francis Crick Institute, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
APAndre Arashiro Pulschen
Andre Arashiro Pulschen
JBJustin Booth
Justin Booth
ASAri Satanowski
Ari Satanowski
CSChristelle Soudy
Christelle Soudy
JCJoaquin Caro-Astorga
Joaquin Caro-Astorga
EDErika DeBenedictis
Erika DeBenedictis
Halogenation enhances the stability and function of pharmaceuticals, biomaterials, and industrial compounds. However, chemical halogenation of molecules and peptides can lack stereoselectivity and require the use of toxic chemicals. Although enzymatic halogenation can improve selectivity and reduce environmental impact, current halogenases are inefficient and insoluble, leading to low yields that limit their applications. Here, we develop RebH Evo4 , a soluble and highly active tryptophan halogenase, containing 12 mutations that confer 37-fold and 44-fold increases in 7-chloro- and 7-bromotryptophan production respectively, in vivo. To create RebH Evo4 , we devise an aminoacyl-tRNA synthetase-based halogenase biosensor and conduct over 500 hours of phage-assisted continuous evolution (PACE). Use of RebH Evo4 in a bioreactor results in the production of 2.7 g/L of halogenated tryptophan. When coupled with a downstream enzyme, RebH Evo4 allows 36-fold increased yields of halogenated tryptamines compared to the wild-type enzyme. Additionally, RebH Evo4 enables efficient production of genetically encoded antimicrobial halogenated peptides. The efficient, site-specific halogenation enabled by our evolved halogenase will accelerate sustainable biomanufacturing of halogenated drugs.

1 January 2026 in Chemical Society Reviews
Verified
Journal Article
Closed access
GFGuilherme Fernandes
Guilherme Fernandes
SKSeong-Heun Kim
Seong-Heun Kim
Jean Leandro Dos SantosJean Leandro Dos Santos
Jean Leandro Dos Santos
YWYuhang Wang
Yuhang Wang
CSChristelle Soudy
Christelle Soudy
MTMatthew Todd
Matthew Todd
We outline major bottlenecks and the clinical pipeline landscape, then present a structure-led analysis of synthetic small-molecule validated leads supported by in vivo data.

8 October 2025 in bioRxiv
Verified
Preprint
Open access
APAndre Arashiro Pulschen
Andre Arashiro Pulschen
JBJustin Booth
Justin Booth
ASAri Satanowski
Ari Satanowski
CSChristelle Soudy
Christelle Soudy
JCJoaquin Caro-Astorga
Joaquin Caro-Astorga
EDErika DeBenedictis
Erika DeBenedictis
Halogenation enhances the stability and function of pharmaceuticals, biomaterials, and industrial compounds. However, chemical halogenation lacks stereoselectivity and requires the use of toxic or expensive chemicals. Although enzymatic halogenation can improve selectivity and reduce environmental impact, current halogenases are inefficient and insoluble, leading to low yields that limit their applications. Here, we develop RebH Evo4 , a soluble and highly active tryptophan halogenase, containing 12 mutations that confer 37-fold and 44-fold increases in 7-chloro and 7-bromotryptophan production respectively, in vivo. To create RebH Evo4 , we devised an aminoacyl tRNA synthetase based halogenase biosensor and conducted over 500 hours of phage-assisted continuous evolution (PACE). Use of RebH Evo4 in a bioreactor resulted in the production of 2.7 g/L of halogenated tryptophan. When coupled with a downstream enzyme, RebH Evo4 allowed 36-fold increased yields of halogenated tryptamines compared to the wild-type enzyme. Additionally, RebH Evo4 enabled efficient production of genetically encoded antimicrobial halogenated peptides. The efficient, site-specific halogenation by our evolved halogenase will accelerate sustainable biomanufacturing of halogenated drugs.

8 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
JMJennifer C Milligan
Jennifer C Milligan
TZTheresa U Zeisner
Theresa U Zeisner
George PapageorgiouGeorge Papageorgiou
George Papageorgiou
DJDhira Joshi
Dhira Joshi
CSChristelle Soudy
Christelle Soudy
JDJohn F.X Diffley
John F.X Diffley
Summary: The coronavirus 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread around the world with unprecedented health and socio-economic effects for the global population. While different vaccines are now being made available, very few antiviral drugs have been approved. The main viral protease (nsp5) of SARS-CoV-2 provides an excellent target for antivirals, due to its essential and conserved function in the viral replication cycle. We have expressed, purified and developed assays for nsp5 protease activity. We screened the nsp5 protease against a custom chemical library of over 5,000 characterised pharmaceuticals. We identified calpain inhibitor I and three different peptidyl fluoromethylketones (FMK) as inhibitors of nsp5 activity in vitro , with IC 50 values in the low micromolar range. By altering the sequence of our peptidomimetic FMK inhibitors to better mimic the substrate sequence of nsp5, we generated an inhibitor with a subnanomolar IC 50 . Calpain inhibitor I inhibited viral infection in monkey-derived Vero E6 cells, with an EC50 in the low micromolar range. The most potent and commercially available peptidyl-FMK compound inhibited viral growth in Vero E6 cells to some extent, while our custom peptidyl FMK inhibitor offered a marked antiviral improvement.